丙戊酸镁缓释片联合碳酸锂治疗躁狂发作的临床分析.pdfVIP

丙戊酸镁缓释片联合碳酸锂治疗躁狂发作的临床分析

目的探讨丙戊酸镁缓释片联合碳酸锂与碳酸锂治疗躁狂发作的疗效与安

全性。方法将52例符合中国精神障碍分类与诊断标准第3版(CCMD-3)躁狂发

作诊断标准的患者随机分为研究组(26例)和对照组(26例),研究组应用丙戊酸镁

缓释片、碳酸锂以及非典型抗精神病药物利培酮。对照组应用碳酸锂联合与利培

酮治疗,疗程6周。用躁狂评定量表(BRMS)与副反应量表(TESS)分别评定疗效及

不良反应观察6周。结果研究组和对照组6周治疗后与治疗前的BRMS评分差

异均具有统计学意义(P＜0.01)，研究组和对照组6周末的BRMS评分及显效率

均具有统计学意义(P＜0.05)，2组的副作用相似,组间主要副作用发生率的差异无

统计学意义(P0.05)。结论丙戊酸镁缓释片联合碳酸锂控制躁狂发作的疗效优于

碳酸锂治疗,安全性良好。

标签：丙戊酸镁缓释片；碳酸锂；躁狂发作

Magnesiumvalproatesustained-releasetabletspluslithiumintreatmentofmanic

episodesofclinicalMUXiao-mei，WEIZhang-li，ZHANGZi-ming，HONGGui-zi，

WANGXiu-mei.TianshuitheThirdPeoplesHospitalofTianshuiCity,Tianshui

741000,China

【Abstract】ObjectveMagnesiumvalproatetabletsoflithiumcarbonateand

lithiumcarbonateintreatmentofjointmanicepisodeoftheefficacyand

safety.Methods52patientsmettheChineseClassificationandDiagnosticCriteriaof

MentalDisordersVersion3(CCMD-3)diagnosticcriteriaformanicepisodewere

randomlydividedintostudygroup(26cases)andcontrolgroup(26

cases),Applicationofmagnesiumvalproategroupsustainedreleasetablets,lithiumand

atypicalantipsychoticrisperidone.Controlgroupwerecombinedlithiumand

risperidone,treatment6w.Maniaratingscaleused(BRMS)andthesideeffectsscale

(TESS)assessedtheefficacyandadversereactionswereobservedfor6weeks.Results

Thestudygroupandcontrolgroupafter6weeksoftreatmentbeforetreatmentBRMS

scoredifferenceswerestatisticallysignificant(P＜0.01),studygroupandcontrol

group,6weeks,andmarkedlyeffectiverateofBRMSscoreswerestatistically

significant(P＜0.05).2groupshadsimilaradverseevents,groups,theincidenceof

majorsideeffectswerenosignificantdifferences(P0.05).ConclusionThe

magnesiumvalproatecombinedlithiumcarbonatecontrolledreleasetabletsmanic